Efficacy and Safety of Metallic Stents in Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine

New Method of Covered Wallstents for Distal Malignant Biliary Obstruction to Reduce Early Stent‐related Complications Based on Characteristics

“…Second, recent improvements in anticancer treatment and in supportive care might affect the clinical outcomes of patients receiving covered Wallstents. In our retrospective analysis, giving gemcitabine did not significantly affect stent patency and stent‐related complications in patients with advanced pancreatic cancer who received SEMS placement, 27 but it is possible that prolonged survival and adverse effects such as myelosuppression due to chemotherapy might have had some influence on outcomes in this study.…”

Stent patency using competing risk model in unresectable pancreatic cancers inserted with biliary self‐expandable metallic stent

“…However, there have been limited data about the factors affecting biliary stent patency in a homogeneous group of patients with pancreatic cancer. In most studies on biliary stents, the definition of patency stems from stent insertion to obstruction, as well as survival of the patient . However, this definition has limitations, in that death without obstruction does not correctly reflect patency of the stent.…”

Endoscopic management of combined malignant biliary and gastric outlet obstruction

“…In pancreatic cancer, chemotherapy with modest intensity was used in the past (i.e. gemcitabine monotherapy, but the current standard regimen is intensified combination therapy such as FOLFIRINOX and a combination therapy of gemcitabine and nab‐paclitaxel . Although these intensified chemotherapeutic regimens prolong survival in metastatic pancreatic cancer from 3 to 6 months to 8 to 11 months, patients are prone to biliary tract infection as well as to gastrointestinal symptoms because of the severe and long‐standing myelosuppression or gastrointestinal toxicities.…”